Promontory Therapeutics Surpasses Efficacy Goals in Phase 2 Trial for Recurrent Thymoma Promontory Therapeutics announced significant progress in its Phase 2 study of PT-112, showing promising results for patients with recurrent thymoma, a rare cancer.

Promontory Therapeutics Surpasses Efficacy Goals in Phase 2 Trial for Recurrent Thymoma #USA #New_York #Promontory_Therapeutics #PT-112 #Thymoma

Promontory Therapeutics Advances Phase 3 Study for Prostate Cancer Drug PT-112 After Successful FDA Meeting Promontory Therapeutics has successfully concluded its End of Phase 2 meeting with the FDA regarding their drug PT-112 for prostate cancer, paving the way for Phase 3 trials.

Promontory Therapeutics Advances Phase 3 Study for Prostate Cancer Drug PT-112 After Successful FDA Meeting #USA #New_York #Prostate_Cancer #Promontory_Therapeutics #PT-112